ID   MT-CHC01R1.5
AC   CVCL_C1L3
DR   cancercelllines; CVCL_C1L3
DR   GEO; GSM3209137
DR   GEO; GSM3209138
DR   Wikidata; Q114312328
RX   PubMed=30979003;
CC   Population: Caucasian; Italian.
CC   Doubling time: 49.1 hours (PubMed=30979003).
CC   Selected for resistance to: ChEBI; CHEBI_175901; Gemcitabine (Gemzar).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4Z41 ! MT-CHC01
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 19-12-24; Version: 6
//
RX   PubMed=30979003; DOI=10.3390/cancers11040519; PMCID=PMC6520787;
RA   Varamo C., Peraldo-Neia C., Ostano P., Basirico M., Raggi C.,
RA   Bernabei P., Venesio T., Berrino E., Aglietta M., Leone F.,
RA   Cavalloni G.;
RT   "Establishment and characterization of a new intrahepatic
RT   cholangiocarcinoma cell line resistant to gemcitabine.";
RL   Cancers (Basel) 11:519.1-519.22(2019).
//